Cargando…
The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity
Encephalopathy of prematurity (EoP) is a major cause of morbidity in preterm neonates, causing neurodevelopmental adversities that can lead to lifelong impairments. Preterm birth‐related insults, such as cerebral oxygen fluctuations and perinatal inflammation, are believed to negatively impact brain...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246971/ https://www.ncbi.nlm.nih.gov/pubmed/33595855 http://dx.doi.org/10.1002/glia.23939 |
_version_ | 1783716424219361280 |
---|---|
author | Vaes, Josine E. G. Brandt, Myrna J. V. Wanders, Nikki Benders, Manon J. N. L. de Theije, Caroline G. M. Gressens, Pierre Nijboer, Cora H. |
author_facet | Vaes, Josine E. G. Brandt, Myrna J. V. Wanders, Nikki Benders, Manon J. N. L. de Theije, Caroline G. M. Gressens, Pierre Nijboer, Cora H. |
author_sort | Vaes, Josine E. G. |
collection | PubMed |
description | Encephalopathy of prematurity (EoP) is a major cause of morbidity in preterm neonates, causing neurodevelopmental adversities that can lead to lifelong impairments. Preterm birth‐related insults, such as cerebral oxygen fluctuations and perinatal inflammation, are believed to negatively impact brain development, leading to a range of brain abnormalities. Diffuse white matter injury is a major hallmark of EoP and characterized by widespread hypomyelination, the result of disturbances in oligodendrocyte lineage development. At present, there are no treatment options available, despite the enormous burden of EoP on patients, their families, and society. Over the years, research in the field of neonatal brain injury and other white matter pathologies has led to the identification of several promising trophic factors and cytokines that contribute to the survival and maturation of oligodendrocytes, and/or dampening neuroinflammation. In this review, we discuss the current literature on selected factors and their therapeutic potential to combat EoP, covering a wide range of in vitro, preclinical and clinical studies. Furthermore, we offer a future perspective on the translatability of these factors into clinical practice. |
format | Online Article Text |
id | pubmed-8246971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82469712021-07-02 The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity Vaes, Josine E. G. Brandt, Myrna J. V. Wanders, Nikki Benders, Manon J. N. L. de Theije, Caroline G. M. Gressens, Pierre Nijboer, Cora H. Glia Review Articles Encephalopathy of prematurity (EoP) is a major cause of morbidity in preterm neonates, causing neurodevelopmental adversities that can lead to lifelong impairments. Preterm birth‐related insults, such as cerebral oxygen fluctuations and perinatal inflammation, are believed to negatively impact brain development, leading to a range of brain abnormalities. Diffuse white matter injury is a major hallmark of EoP and characterized by widespread hypomyelination, the result of disturbances in oligodendrocyte lineage development. At present, there are no treatment options available, despite the enormous burden of EoP on patients, their families, and society. Over the years, research in the field of neonatal brain injury and other white matter pathologies has led to the identification of several promising trophic factors and cytokines that contribute to the survival and maturation of oligodendrocytes, and/or dampening neuroinflammation. In this review, we discuss the current literature on selected factors and their therapeutic potential to combat EoP, covering a wide range of in vitro, preclinical and clinical studies. Furthermore, we offer a future perspective on the translatability of these factors into clinical practice. John Wiley & Sons, Inc. 2020-11-30 2021-06 /pmc/articles/PMC8246971/ /pubmed/33595855 http://dx.doi.org/10.1002/glia.23939 Text en © 2020 The Authors. GLIA published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles Vaes, Josine E. G. Brandt, Myrna J. V. Wanders, Nikki Benders, Manon J. N. L. de Theije, Caroline G. M. Gressens, Pierre Nijboer, Cora H. The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity |
title | The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity |
title_full | The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity |
title_fullStr | The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity |
title_full_unstemmed | The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity |
title_short | The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity |
title_sort | impact of trophic and immunomodulatory factors on oligodendrocyte maturation: potential treatments for encephalopathy of prematurity |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246971/ https://www.ncbi.nlm.nih.gov/pubmed/33595855 http://dx.doi.org/10.1002/glia.23939 |
work_keys_str_mv | AT vaesjosineeg theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT brandtmyrnajv theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT wandersnikki theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT bendersmanonjnl theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT detheijecarolinegm theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT gressenspierre theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT nijboercorah theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT vaesjosineeg impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT brandtmyrnajv impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT wandersnikki impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT bendersmanonjnl impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT detheijecarolinegm impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT gressenspierre impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity AT nijboercorah impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity |